Treating MDS organoids with the mTOR inhibitor everolimus partially rescued these phenotypes, highlighting mTOR signaling as a key mediator of disease progression and a potential therapeutic target in LIS1-lissencephaly. Here, MTOR is linked to lissencephaly spectrum disorders.